These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29887371)

  • 1. Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis.
    Chan XHS; Win YN; Mawer LJ; Tan JY; Brugada J; White NJ
    Lancet Infect Dis; 2018 Aug; 18(8):913-923. PubMed ID: 29887371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.
    van der Pluijm RW; Tripura R; Hoglund RM; Pyae Phyo A; Lek D; Ul Islam A; Anvikar AR; Satpathi P; Satpathi S; Behera PK; Tripura A; Baidya S; Onyamboko M; Chau NH; Sovann Y; Suon S; Sreng S; Mao S; Oun S; Yen S; Amaratunga C; Chutasmit K; Saelow C; Runcharern R; Kaewmok W; Hoa NT; Thanh NV; Hanboonkunupakarn B; Callery JJ; Mohanty AK; Heaton J; Thant M; Gantait K; Ghosh T; Amato R; Pearson RD; Jacob CG; Gonçalves S; Mukaka M; Waithira N; Woodrow CJ; Grobusch MP; van Vugt M; Fairhurst RM; Cheah PY; Peto TJ; von Seidlein L; Dhorda M; Maude RJ; Winterberg M; Thuy-Nhien NT; Kwiatkowski DP; Imwong M; Jittamala P; Lin K; Hlaing TM; Chotivanich K; Huy R; Fanello C; Ashley E; Mayxay M; Newton PN; Hien TT; Valecha N; Smithuis F; Pukrittayakamee S; Faiz A; Miotto O; Tarning J; Day NPJ; White NJ; Dondorp AM;
    Lancet; 2020 Apr; 395(10233):1345-1360. PubMed ID: 32171078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial.
    Muhindo MK; Jagannathan P; Kakuru A; Opira B; Olwoch P; Okiring J; Nalugo N; Clark TD; Ruel T; Charlebois E; Feeney ME; Havlir DV; Dorsey G; Kamya MR
    Lancet Infect Dis; 2019 Sep; 19(9):962-972. PubMed ID: 31307883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
    West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
    Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.
    Manning J; Vanachayangkul P; Lon C; Spring M; So M; Sea D; Se Y; Somethy S; Phann ST; Chann S; Sriwichai S; Buathong N; Kuntawunginn W; Mitprasat M; Siripokasupkul R; Teja-Isavadharm P; Soh E; Timmermans A; Lanteri C; Kaewkungwal J; Auayporn M; Tang D; Chour CM; Prom S; Haigney M; Cantilena L; Saunders D
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6056-67. PubMed ID: 25092702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial.
    Desai M; Gutman J; L'lanziva A; Otieno K; Juma E; Kariuki S; Ouma P; Were V; Laserson K; Katana A; Williamson J; ter Kuile FO
    Lancet; 2015 Dec; 386(10012):2507-19. PubMed ID: 26429700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania.
    Baiden R; Oduro A; Halidou T; Gyapong M; Sie A; Macete E; Abdulla S; Owusu-Agyei S; Mulokozi A; Adjei A; Sevene E; Compaoré G; Valea I; Osei I; Yawson A; Adjuik M; Akparibo R; Ogutu B; Upunda GL; Smith P; Binka F
    Malar J; 2015 Apr; 14():160. PubMed ID: 25885858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnant women with HIV from Gabon and Mozambique: a randomised, double-blind, placebo-controlled trial.
    González R; Nhampossa T; Mombo-Ngoma G; Mischlinger J; Esen M; Tchouatieu AM; Mendes A; Figueroa-Romero A; Zoleko-Manego R; Lell B; Lagler H; Stoeger L; Dimessa LB; El Gaaloul M; Sanz S; Méndez S; Piqueras M; Sevene E; Ramharter M; Saúte F; Menendez C;
    Lancet Infect Dis; 2024 May; 24(5):476-487. PubMed ID: 38224706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-label, superiority trial.
    Ahmed R; Poespoprodjo JR; Syafruddin D; Khairallah C; Pace C; Lukito T; Maratina SS; Asih PBS; Santana-Morales MA; Adams ER; Unwin VT; Williams CT; Chen T; Smedley J; Wang D; Faragher B; Price RN; Ter Kuile FO
    Lancet Infect Dis; 2019 Sep; 19(9):973-987. PubMed ID: 31353217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis.
    Gutman J; Kovacs S; Dorsey G; Stergachis A; Ter Kuile FO
    Lancet Infect Dis; 2017 Feb; 17(2):184-193. PubMed ID: 27865890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study.
    van der Pluijm RW; Imwong M; Chau NH; Hoa NT; Thuy-Nhien NT; Thanh NV; Jittamala P; Hanboonkunupakarn B; Chutasmit K; Saelow C; Runjarern R; Kaewmok W; Tripura R; Peto TJ; Yok S; Suon S; Sreng S; Mao S; Oun S; Yen S; Amaratunga C; Lek D; Huy R; Dhorda M; Chotivanich K; Ashley EA; Mukaka M; Waithira N; Cheah PY; Maude RJ; Amato R; Pearson RD; Gonçalves S; Jacob CG; Hamilton WL; Fairhurst RM; Tarning J; Winterberg M; Kwiatkowski DP; Pukrittayakamee S; Hien TT; Day NP; Miotto O; White NJ; Dondorp AM
    Lancet Infect Dis; 2019 Sep; 19(9):952-961. PubMed ID: 31345710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial.
    Sevene E; Banda CG; Mukaka M; Maculuve S; Macuacua S; Vala A; Piqueras M; Kalilani-Phiri L; Mallewa J; Terlouw DJ; Khoo SH; Lalloo DG; Mwapasa V
    Malar J; 2019 Aug; 18(1):277. PubMed ID: 31429785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.
    Sutanto I; Soebandrio A; Ekawati LL; Chand K; Noviyanti R; Satyagraha AW; Subekti D; Santy YW; Crenna-Darusallam C; Instiaty I; Budiman W; Prasetya CB; Lardo S; Elyazar I; Duparc S; Cedar E; Rolfe K; Fernando D; Berni A; Jones S; Kleim JP; Fletcher K; Sharma H; Martin A; Taylor M; Goyal N; Green JA; Tan LK; Baird JK
    Lancet Infect Dis; 2023 Oct; 23(10):1153-1163. PubMed ID: 37236221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial.
    Stone W; Mahamar A; Smit MJ; Sanogo K; Sinaba Y; Niambele SM; Sacko A; Keita S; Dicko OM; Diallo M; Maguiraga SO; Samake S; Attaher O; Lanke K; Ter Heine R; Bradley J; McCall MBB; Issiaka D; Traore SF; Bousema T; Drakeley C; Dicko A
    Lancet Microbe; 2022 May; 3(5):e336-e347. PubMed ID: 35544095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrocardiographic Safety of Repeated Monthly Dihydroartemisinin-Piperaquine as a Candidate for Mass Drug Administration.
    Millat-Martínez P; Ila R; Laman M; Robinson L; Karunajeewa H; Abel H; Pulai K; Sanz S; Manning L; Moore B; Bassat Q; Mitjà O
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.
    Ratcliff A; Siswantoro H; Kenangalem E; Maristela R; Wuwung RM; Laihad F; Ebsworth EP; Anstey NM; Tjitra E; Price RN
    Lancet; 2007 Mar; 369(9563):757-765. PubMed ID: 17336652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial.
    Barsosio HC; Madanitsa M; Ondieki ED; Dodd J; Onyango ED; Otieno K; Wang D; Hill J; Mwapasa V; Phiri KS; Maleta K; Taegtmeyer M; Kariuki S; Schmiegelow C; Gutman JR; Ter Kuile FO
    Lancet; 2024 Jan; 403(10424):365-378. PubMed ID: 38224710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial.
    Kajubi R; Ochieng T; Kakuru A; Jagannathan P; Nakalembe M; Ruel T; Opira B; Ochokoru H; Ategeka J; Nayebare P; Clark TD; Havlir DV; Kamya MR; Dorsey G
    Lancet; 2019 Apr; 393(10179):1428-1439. PubMed ID: 30910321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
    Hamaluba M; van der Pluijm RW; Weya J; Njuguna P; Ngama M; Kalume P; Mwambingu G; Ngetsa C; Wambua J; Boga M; Mturi N; Lal AA; Khuroo A; Taylor WRJ; Gonçalves S; Miotto O; Dhorda M; Mutinda B; Mukaka M; Waithira N; Hoglund RM; Imwong M; Tarning J; Day NPJ; White NJ; Bejon P; Dondorp AM
    Lancet Infect Dis; 2021 Oct; 21(10):1395-1406. PubMed ID: 34111412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.